

RESTRICTION PRESENTED

The claims have been restricted into the following groups of inventions:

<u>Groups</u>	<u>Claims</u>	<u>Subject Matter</u>
1	8-16, 30-37, and 86, each in part	Drawn to variants of SCN1A channels and nucleic acids encoding same.
2	8-16, 30-37, and 86, each in part	Drawn to variants of SCN1B channels and nucleic acids encoding same.
3	8-16, 30-37, and 86, each in part	Drawn to variants of SCN2A channels and nucleic acids encoding same.
4	8-16, 30-37, and 86, each in part	Drawn to variants of CHRNA5 channels and nucleic acids encoding same.
5	8-16, 30-37, and 86, each in part	Drawn to variants of CHRNA2 channels and nucleic acids encoding same.
6	8-16, 30-37, and 86, each in part	Drawn to variants of CHRNA3 channels and nucleic acids encoding same.
7	8-16, 30-37, and 86, each in part and 17-18 in their entirety	Drawn to variants of KCNQ2 channels and nucleic acids encoding same.
8	8-16, 30-37, and 86, each in part	Drawn to variants of KCNQ3 channels and nucleic acids encoding same.
9	8-16, 30-37, and 86, each in part	Drawn to variants of GABRB1 channels and nucleic acids encoding same.
10	8-16, 30-37, and 86, each in part	Drawn to variants of GABRG3 channels and nucleic acids encoding same.
11	8-16, 30-37, and 86, each in part	Drawn to variants of GABRA1 channels and nucleic acids encoding same.
12	8-16, 30-37, and 86, each in part	Drawn to variants of GABRA2 channels and nucleic acids encoding same.

13	8-16, 30-37, and 86, each in part	Drawn to variants of GABRA5 channels and nucleic acids encoding same.
14	8-16, 30-37, and 86, each in part	Drawn to variants of GABRB2 channels and nucleic acids encoding same.
15	8-16, 30-37, and 86, each in part	Drawn to variants of GABRPi channels and nucleic acids encoding same.
16	8-16, 30-37, and 86, each in part	Drawn to variants of GABRB3 channels and nucleic acids encoding same.
17	8-16, 30-37, and 86, each in part	Drawn to variants of GABRD channels and nucleic acids encoding same.

#### APPLICANTS' ELECTION

Applicants hereby elect the invention of **Group I, claims 8-16, 30-37, and 86**, each in part, drawn to variants of SCN1A channels and nucleic acids encoding same, for prosecution at this time.

#### REMARKS

Claims 8-18, 30-37 and 86 are now pending in the subject U.S. patent application. Claims 8-18, 30-37 and 86 as filed have been subjected to a Restriction/Election Requirement.

In response to the Restriction/Election Requirement, applicants have elected the claims of Group I, claims 8-16, 30-37, and 86, each in part, drawn to variants of SCN1A channels and nucleic acids encoding same, for prosecution at this time. As requested by the Patent Office and in an effort to expedite prosecution, applicants respectfully submit that SEQ ID NOS. 1-9 correspond to variants of SCN1A channels and nucleic

acids encoding same. As such, SEQ ID NOS. 1-9 correspond to the elected invention of Group I, claims 8-16, 30-37, and 86.

Applicants hereby reserve the right to file one or more divisional patent applications directed to the unelected subject matter.

CONCLUSION

Should there be any minor issues outstanding in this matter, the Examiner is respectfully requested to telephone the undersigned attorney. Early passage of the subject application to issue is earnestly solicited.

DEPOSIT ACCOUNT

The Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account Number 50-0426.

Respectfully submitted,

JENKINS, WILSON, TAYLOR & HUNT, P.A.

Date: 12/7/2010

By: 

Arles A. Taylor, Jr.  
Registration No. 39,395  
Customer No. 25297  
(919) 493-8000

1386/23      AAT/LRL/dbp